AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03971422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study NCT01596517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
Description: Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
Study NCT03971422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time points.
Study NCT04463992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program participants
Description: The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
Study NCT04463992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT04463992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by local oncologists
Study NCT03628534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline Enhanced Radiofrequency (SERF) ablation
Description: Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Study NCT01565655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT01565655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03226574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
Study NCT02478216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
Study NCT01535209 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: 18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
Study NCT01535209 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy (WBRT)
Description: 10 x 3 Gy to whole brain
Study NCT05623826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive- behavioral imagery-based training
Description: The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
Study NCT03583801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory aromatherapy
Description: 2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
Study NCT03583801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without aromatherapy
Description: no intervention
Study NCT00283621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp (darbepoetin alfa)
Study NCT00283621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta (pegfilgrastim)
Study NCT00283621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT02481297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein given on Day 1 of each 28 day cycle.
Study NCT00283621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT02842736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerene(R) Cryotherapy Device
Study NCT02481297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
Study NCT00820469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375
Description: rituximab 375 mg/m2 IV weekly, during 4 weeks
Study NCT00820469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab 1000
Description: rituximab 1000 mg IV, two infusions on day 1 and day 15
Study NCT03265626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 2: Awareness creation and community mobilization
Description: Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
Study NCT03265626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: available standard care
Description: The standard care will be maintained but no other additional intevvenion designed by this study
Study NCT05703529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
Study NCT05703529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care means treating as usual, including a regular home visit.
Study NCT00836875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.
Study NCT04981379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
Study NCT04981379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
Study NCT04981379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir + Hydroxychloroquine
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Study NCT04981379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Study NCT00786318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: ziprasidone 20mg IM
Study NCT00786318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Haldol 5mg/ Ativan 2mg IM
Study NCT03282890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHRP-BB
Description: The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
Study NCT02548208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum focused extracorporeal shockwave
Description: the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
Study NCT02548208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham shock wave
Description: Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
Study NCT01111617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI feedback
Description: Patients receive real-time fMRI biofeedback to modulate pain
Study NCT02386982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Study NCT04089761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Study NCT03631342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCV20
Description: controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
Study NCT03631342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCV40
Description: volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
Study NCT03631342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV
Description: controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
Study NCT01855594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 250 mg/tablet, 6 weeks course of oral administration
Study NCT01855594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet, 6 week course of oral administration
Study NCT03631342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV+Tins
Description: controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
Study NCT03631342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV
Description: ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
Study NCT00704366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral, tablet, once daily, dose will be variable
Study NCT01504126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Undergo standard chemotherapy
Study NCT01504126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO
Study NCT01504126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01504126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT01980186 — intervention group
Intervention type: DEVICE
Intervention: TUS transcranial 2D ultrasound
Study NCT00895115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given once daily
Study NCT03456986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH neurotraining
Description: Tunes up the center of the motion discrimination (dorsal stream) working range
Study NCT03456986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation Discrimination
Description: Tunes up the ventral stream most sensitive to high contrast and colored patterns.
Study NCT00582634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
Study NCT00389168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Titrated to 300 mg od, 48 weeks.
Study NCT00389168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Titrated to 100 mg od, 48 weeks.
Study NCT02492009 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Study NCT02492009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Decision Aid
Description: The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
Study NCT03761979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strontium L-lactate
Description: The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
Study NCT02928328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA oral solution
Description: Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
Study NCT00981565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open carpal tunnel release
Description: surgery to release the carpal tunnel
Study NCT02928328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular GABA
Description: The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
Study NCT02928328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain modulation
Description: The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
Study NCT04605757 — intervention group
Intervention type: OTHER
Intervention: Clinical, functional and radiological lung involvement evolution
Description: Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
Study NCT04990986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Complex intervention
Description: Will be co-developed during the study.
Study NCT00945503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 is a GT1 recepor antagonist
Study NCT04063033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron - Sodium Ferric Gluconate Complex
Description: IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
Study NCT02485912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z
Description: This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
Study NCT02485912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z
Description: This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
Study NCT00981565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Night-cast
Description: individual night time splinting
Study NCT00790972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinofresh
Description: two sprays in each nostril three times daily for one week
Study NCT00790972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two sprays in each nostril three times daily for one week
Study NCT03804060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermogard XP3
Description: Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
Study NCT03804060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recanalization only
Description: Standard of Care for recanalization
Study NCT01473537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium lactate solution
Description: Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
Study NCT01473537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: calcium lactate solution
Description: Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
Study NCT00566397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700
Description: 15 mg for 6 days followed by daily dosing of 5mg
Study NCT00566397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700
Description: 60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
Study NCT00566397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04703647 — intervention group
Intervention type: OTHER
Intervention: Administration of questionnaires for prospective group
Description: Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
Study NCT04703647 — intervention group
Intervention type: OTHER
Intervention: Blood samples for prospective group
Description: Blood samples at T0,T1,T2 and T3.
Study NCT04703647 — intervention group
Intervention type: OTHER
Intervention: Blood samples for control group
Description: Blood samples just one time
Study NCT02575807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion
Study NCT02289885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoScape
Description: Ultrasonography device
Study NCT02465606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
Study NCT02465606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Description: Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.